Emil ter Veer

753 total citations
24 papers, 481 citations indexed

About

Emil ter Veer is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Emil ter Veer has authored 24 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 12 papers in Surgery and 8 papers in Oncology. Recurrent topics in Emil ter Veer's work include Gastric Cancer Management and Outcomes (22 papers), Esophageal Cancer Research and Treatment (11 papers) and Metastasis and carcinoma case studies (5 papers). Emil ter Veer is often cited by papers focused on Gastric Cancer Management and Outcomes (22 papers), Esophageal Cancer Research and Treatment (11 papers) and Metastasis and carcinoma case studies (5 papers). Emil ter Veer collaborates with scholars based in Netherlands, Germany and United States. Emil ter Veer's co-authors include Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven, Nadia Haj Mohammad, Lok Lam Ngai, Gert van Valkenhoef, Maarten Anderegg, Jessy Joy van Kleef, Mirjam A. G. Sprangers, Tom van den Ende and Maarten C.C.M. Hulshof and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Scientific Reports.

In The Last Decade

Emil ter Veer

24 papers receiving 477 citations

Peers

Countries citing papers authored by Emil ter Veer

Since Specialization

Citations

This map shows the geographic impact of Emil ter Veer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emil ter Veer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emil ter Veer more than expected).

Fields of papers citing papers by Emil ter Veer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emil ter Veer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emil ter Veer. The network helps show where Emil ter Veer may publish in the future.

Co-authorship network of co-authors of Emil ter Veer

This figure shows the co-authorship network connecting the top 25 collaborators of Emil ter Veer. A scholar is included among the top collaborators of Emil ter Veer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emil ter Veer. Emil ter Veer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis 2019 ·JNCI Journal of the National Cancer Institute ·Jessy Joy van Kleef, Emil ter Veer, Héctor G. van den Boorn, Sandor Schokker, Lok Lam Ngai, (unknown), Nadia Haj Mohammad, Lonneke V. van de Poll‐Franse, Aeilko H. Zwinderman, Martijn G.H. van Oijen, Mirjam A. G. Sprangers, Hanneke W.M. van Laarhoven	40
2	The Use of (Network) Meta-Analysis in Clinical Oncology 2019 ·Frontiers in Oncology ·Emil ter Veer, Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven	51
3	COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis 2019 ·Frontiers in Oncology ·Tom van den Ende, (unknown), Héctor G. van den Boorn, Emil ter Veer, Maarten C.C.M. Hulshof, Suzanne S. Gisbertz, Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven	11
4	SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer 2019 ·Cancers ·(unknown), Ameen Abu‐Hanna, Emil ter Veer, (unknown), Florian Lordick, M. Stahl, Jaffer A. Ajani, Rosine Guimbaud, (unknown), Susan Dutton, Yung‐Jue Bang, Narikazu Boku, (unknown), Mirjam A. G. Sprangers, Rob H.A. Verhoeven, Aeilko H. Zwinderman, Martijn van Oijen, Hanneke W. M. van Laarhoven	18
5	The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis 2019 ·Cancers ·Tom van den Ende, Emil ter Veer, (unknown), (unknown), (unknown), (unknown), (unknown), Suzanne S. Gisbertz, Maarten C.C.M. Hulshof, Martijn G.H. van Oijen, Hanneke W. M. van Laarhoven	33
6	Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis 2019 ·Cancers ·Tom van den Ende, Emil ter Veer, (unknown), Mark I. van Berge Henegouwen, Maarten C.C.M. Hulshof, Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven	20
7	TOXview: a novel graphical presentation of cancer treatment toxicity profiles 2019 ·Acta Oncologica ·Lok Lam Ngai, Emil ter Veer, Héctor G. van den Boorn, (unknown), Jessy Joy van Kleef, Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven	5
8	Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis 2018 ·European Journal of Cancer ·Emil ter Veer, Jessy Joy van Kleef, Sandor Schokker, (unknown), (unknown), Nadia Haj Mohammad, Mirjam A. G. Sprangers, Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven	27
9	Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review 2018 ·Gastric Cancer ·Emil ter Veer, Jessy Joy van Kleef, Mirjam A. G. Sprangers, Nadia Haj Mohammad, Martijn G.H. van Oijen, Hanneke W. M. van Laarhoven	15
10	Two novel registry-based prediction models for overall survival in patients with metastatic esophageal or gastric cancer. 2018 ·Journal of Clinical Oncology ·(unknown), Ameen Abu‐Hanna, Emil ter Veer, Jessy Joy van Kleef, Florian Lordick, M. Stahl, Jaffer A. Ajani, Rosine Guimbaud, Se Hoon Park, Susan Dutton, Yung‐Jue Bang, Nadia Haj Mohammad, Mirjam A. G. Sprangers, Rob H.A. Verhoeven, Aeilko H. Zwinderman, Martijn G.H. van Oijen, Hanneke W. M. van Laarhoven	1
11	Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis 2018 ·Acta Oncologica ·Emil ter Veer, Tom van den Ende, Aafke Creemers, (unknown), Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven	11
12	Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis 2017 ·Scientific Reports ·Emil ter Veer, Lok Lam Ngai, Gert van Valkenhoef, Nadia Haj Mohammad, Maarten Anderegg, Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven	20
13	Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis 2017 ·Scientific Reports ·Aafke Creemers, Emil ter Veer, (unknown), Paul Lodder, Gerrit K. Hooijer, Nicole C.T. van Grieken, Maarten F. Bijlsma, Sybren L. Meijer, Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven	11
14	Comparison of cytotoxic backbones for first line trastuzumab-containing regimens in HER2-positive advanced esophagogastric cancer: A meta-analysis 2017 ·Annals of Oncology ·Emil ter Veer, Aafke Creemers, (unknown), Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven	1
15	Prognostic and predictive factors for overall survival (OS) in metastatic esophagogastric cancer (EGC): A meta-analysis. 2017 ·Journal of Clinical Oncology ·Emil ter Veer, Jessy Joy van Kleef, Sandor Schokker, (unknown), (unknown), Nadia Haj Mohammad, Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven	1
16	The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis 2016 ·Gastric Cancer ·Emil ter Veer, Nadia Haj Mohammad, Paul Lodder, Lok Lam Ngai, (unknown), Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven	30
17	Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature 2016 ·Cancer and Metastasis Reviews ·Emil ter Veer, Nadia Haj Mohammad, Gert van Valkenhoef, Lok Lam Ngai, (unknown), Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven	32
18	The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis 2016 ·JNCI Journal of the National Cancer Institute ·Emil ter Veer, Nadia Haj Mohammad, Gert van Valkenhoef, Lok Lam Ngai, (unknown), Maarten Anderegg, Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven	86
19	Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis 2015 ·Cancer and Metastasis Reviews ·Nadia Haj Mohammad, Emil ter Veer, Lok Lam Ngai, (unknown), Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven	39
20	First-line doublet or triplet chemotherapy for advanced esophagogastric cancer: A systematic review and meta-analysis. 2015 ·Journal of Clinical Oncology ·Nadia Haj Mohammad, Emil ter Veer, Lok Lam Ngai, (unknown), Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact